EAGAN, Minn.--(BUSINESS WIRE)--Biothera today announced the appointment of Patricia Molloy, M.D. as Chief Medical Officer. In this role, Dr. Molloy is responsible for the clinical development of Imprime PGG®, the company’s immunotherapeutic oncology drug that is currently in multiple clinical trials for colorectal and lung cancer and chronic lymphocytic leukemia.
